IT solutions for imaging biomarkers in biopharmaceutical research and development

IBM Systems Journal

Volumn 46, Issue 1, 2007, Pages 183-198

  Hehenberger, Michael ^a   Chatterjee, Avijit ^a   Reddy, Usha ^a   Hernandez, Joyce ^b   Sprengel, Jörg ^c  

^a IBM   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c IBM   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BIOMARKERS; DRUG PRODUCTS; INFORMATION TECHNOLOGY; PATHOGENS;

BIOPHARMACEUTICAL INDUSTRY; IMAGING BIOMARKERS;

IMAGING TECHNIQUES;

EID: 33947149136     PISSN: 00188670     EISSN: None     Source Type: Journal    
DOI: 10.1147/sj.461.0183     Document Type: Article

References (48)

1. J. A. DiMasi, "The Value of Improving the Productivity of the Drug Development Process: Faster Times and Better Decisions," PharmacoEconomics 20, Supplement 3, 1-10 (2002).
2. J. A. DiMasi, R. W. Hansen, and H. G. Grabowski, "The Price of Innovation: New Estimates of Drug Development Costs," Journal of Health Economics 22, No. 2, 151-185 (2003).
3. Pharma 2010: The Threshold of Innovation, IBM Business Consulting Services, http://www.ibm.com/industries/healthcare/doc/content/resource/ insight/941673105.html?g_type=rhc.
4. F. W. Frueh, PGx and BIOMARKERS: Current Role in Drug Development, U. S. Department of Health and Human Services, Food and Drug Administration (June 2005), http://www.fda.gov/cder/genomics/PGX_biomarkers. pdf.
5. Challenge and Opportunity on the Critical Path to New Medical Products, U. S. Department of Health and Human Services, Food and Drug Administration (March 2004), http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html.
6. L. J. Lesko and A. J. Atkinson, Jr., "Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies," Annual Review of Pharmacology and Toxicology 41, 347-366 (2001).
7. J. G. Hardy and C. G. Wilson, "Radionuclide Imaging in Pharmaceutical, Physiological and Pharmacological Research," Clinical Physics and Physiological Measurement 2, No. 2, 71-121 (May 1981).
8. K. Sikora, H. Smedley, and P. Thorpe, "Tumour Imaging and Drug Targeting," British Medical Bulletin 40, No. 3, 233-239 (July 1984).
9. A. J. Fischman, N. M. Alpert, and R. H. Rubin, "Pharmacokinetic Imaging: A Noninvasive Method for Determining Drug Distribution and Action," Clinical Pharmacokinetics 41, No. 8, 581-602 (2002).
10. J. J. Smith, A. G. Sorensen, and J. H. Thrall, "Biomarkers in Imaging: Realizing Radiology's Future," Radiology 227, No. 3, 633-638 (2003).
11. M. Rudin and R. Weissleder, "Molecular Imaging in Drug Discovery and Development," Nature Reviews Drug Discovery Volume 2, Part 2, 123-131 (2003).
12. F. Jaffer and R. Weissleder, "Molecular Imaging in the Clinical Arena," Journal of the American Medical Association 293, No. 7, 855-862 (2005).
13. H. Mucke, Molecular Imaging Comes of Age, Applications and Impacts in Discovery, Clinical Trials, and Medical Practice, Cambridge Health Associates (CHA) Life Sciences Reports (October 2004).
14. H. H. Pien, A. J. Fischman, J. H. Thrall, and A. G. Sorensen, "Using Imaging Biomarkers to Accelerate Drug Development and Clinical Trials," Drug Discovery Today 10, No. 4, 259-266 (February 2005).
15. N. Beckmann, D. Laurent, B. Tigani, R. Panizzutti, and M. Rudin, "Magnetic Resonance Imaging in Drug Discovery: Lessons from Disease Areas," Drug Discovery Today 9, No. 1, 35-42 (January 2004).
16. A. G. Sorensen, "Magnetic Resonance as a Cancer Imaging Biomarker," Journal of Clinical Oncology 24, No. 20, 3274-3281 (July 2006).
17. N. Hylton, "Dynamic Contrast-Enhanced Magnetic Resonance Imaging as an Imaging Biomarker," Journal of Clinical Oncology 24, No. 20, 3293-3298 (July 2006).
18. W. A. Weber, "Positron Emission Tomography as an Imaging Biomarker," Journal of Clinical Oncology 24, No. 20, 3282-92 (July 2006).
19. J. T. Salonen, K. Nyyssonen, R. Salonen, E. Porkkala-Sarataho, T.-P. Tuomainen, U. Diczfalusy, and I. Bjorkhem, "Lipoprotein Oxidation and Progression of Carotid Atherosclerosis," Circulation 95, No. 4, 840-845 (1997).
20. D. A. Lewin and M. P. Weiner, "Molecular Biomarkers in Drug Development," Drug Discovery Today 9, No. 22, 976-983 (November 2004).
21. N. Davies, T. Peakman, and S. Arlington, "A New Formula for Finding Drugs," Drug Discovery Today 9, No. 5, 197-199 (March 2004).
22. R. Frank and R. Hargreaves, "Clinical Biomarkers in Drug Discovery and Development," Nature Reviews Drug Discovery Volume 2, Part 7, 566-580 (July 2003).
23. A. R. Wolfe, M. Mendizabal, E. Leong, A. Cuthbertson, V. Desai, S. Pullan, D. K. Fujii, M. Morrison, R. Pither, and S. A. Waldman, "In Vivo Imaging of Human Colon Cancer Xenografts in Immunodeficient Mice Using a Guanylyl Cyclase C-Specific Ligand," Journal of Nuclear Medicine 43, No. 3, 392-399 (2002).
24. A. Bayes-Genis, C. A. Conover, M. T. Overgaard, K. R. Bailey, M. Christiansen, D. R. Holmes, Jr., R. Virmani, C. Oxvig, and R. S. Schwartz, "Pregnancy-Associated Plasma Protein A as a Marker of Acute Coronary Syndromes," New England Journal of Medicine 345, No. 14, 1022-1029 (October 2001).
25. G. Geskin, C. M. Kramer, W. J. Rogers, T. M. Theobald, D. Pakstis, Y. L. Hu, and N. Reichek, "Quantitative Assessment of Myocardial Viability after Infarction by Dobutamine Magnetic Resonance Tagging," Circulation 98, No. 3, 217-223 (July 1998).
26. S. G. Reich, M. B. Lederman, and M. E. Griswold, "Errors and Delays in Diagnosing Parkinson's Disease," Annals of Neurology 52, No. S3, p. S84 (2002).
27. D. L. Jennings, J. P. Seibyl, D. Oakes, S. Eberly, J. Murphy, and K. Marek, "(123I) beta-CIT and Single-Photon Emission Computed Tomographic Imaging vs Clinical Evaluation in Parkinsonian Syndrome: Unmasking an Early Diagnosis," Archives of Neurology 61, No. 8, 1224-1229 (August 2004).
28. B. J. Hillman, "Introduction to the Special Issue on Medical Imaging in Oncology," Journal of Clinical Oncology 24, No. 20, 3223-3224 (July 2006).
29. M. Atri, "New Technologies and Directed Agents for Applications of Cancer Imaging," Journal of Clinical Oncology 24, No. 20, 3299-3308 (July 2006).
30. M. E. Juweid and B. D. Cheson, "Positron-Emission Tomography and Assessment of Cancer Therapy," New England Journal of Medicine 354, No. 5, 496-507 (February 2006).
31. Study Data Specifications Version 1.3, U. S. Food and Drug Administration (2006), http://www.fda.gov/cder/regulatory/ersr/ Studydata-v1.3.pdf.
32. HUGO Gene Nomenclature Committee, http://www.gene.ucl.ac.uk/ nomenclature/.
33. Entrez PubMed, U. S. National Library of Medicine, http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed.
34. GenBank Overview, National Center for Biotechnology Information http:// www.ncbi.nlm.nih.gov/Genbank.
35. Single Nucleotide Polymorphism, National Center for Biotechnology Information, http://www.ncbi.nlm.nih.gov/SNP.
36. UniProtKB/Swiss-Prot, European Bioinformatics Institute, http:// www.ebi.ac.uk/swissprot/.
37. M. Pivovarov, G. Bhandary, U. Mahmood, G. Zahlmann, M. Naraghi, and R. Weissleder, "MIPortal: A High Capacity Server for Molecular Imaging Research," Molecular Imaging 4, No. 4, 425-431 (October-December 2005).
38. C. Amies, A. Bani-Hashemi, J. C. Celi, G. Grousset, F. Ghelmansarai, D. Hristov, D. Lane, M. Mitschke, A. Singh, H. Shukla, J. Stein, and M. Wofford, "A Multi-Platform Approach to Image Guided Radiation Therapy (IGRT)," Medical Dosimetry 31, No. 1, 12-19 (Spring 2006).
39. Oracle Clinical, Oracle Corporation, http://www.oracle.com/industries/ life_sciences/oc_data_sheet-81202.pdf.
40. CDMS with Clintrial, Phase Forward, http://www.phaseforward.com/ products_cdms_clintrial.html.
41. IBM SCORE: The Next Generation in Compliance Solutions, IBM Corporation, http://www.ibm.com/industries/healthcare/doc/content/landingdtw/ 1160437105.html?g_type=pspot.
42. IBM WebSphere Information Integrator, http://www.ibm.com/industries/ healthcare/doc/content/solution/939513105.html.
43. IBM Data Discovery and Query Builder, http://publib.boulder.ibm.com/ infocenter/eserver/v1r2/index.jsp?topic=/ddqb/eicavkickoff.htm.
44. JSR 170: Content Repository for Java Technology API, Java Community Process, http://jcp.org/en/jsr/detail?id=170.
45. JSR 168: Portlet Specification, Java Community Process, http://jcp.org/ en/jsr/detail?id=168.
46. G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, L. Shankar, S. M. Larson, C. C. Sigman, R. L. Schilsky, and D. C. Sullivan, "Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development," Clinical Cancer Research 11, No. 8, 2785-2808 (April 2005).
47. Alzheimer's Disease Neuroimaging Initiative Questions and Answers, U. S. National Institutes of Health, National Institute on Aging (October 13, 2004), http://www.nia.nih.gov/NewsAndEvents/PressReleases/ PR20041013ADNI.htm.
48. T. Sunderland, H. Hampel, M. Takeda, K. T. Putnam, and R. M. Cohen, "Biomarkers in the Diagnosis of Alzheimer's Disease: Are We Ready?" Journal of Geriatric Psychiatry and Neurology 19, No. 3, 172-179 (September 2006).